Clinical Trial

Exploring the Modulatory Effect of the Dialyzer Membrane Choice on Hemodialysisassociated Thromboinflammation: a Prospective Randomized Cross-over Trial

Study acronym: CELL-ACT-MEMBR
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trial investigates whether the dialyzer membrane influences hemodialysis-associated thromboinflammation. Specifically, it evaluates the effects of 3 commercially available dialyzer membrane types on immune cell activation and thromboinflammatory responses. During this trial, participants will undergo standard hemodialysis (3 sessions/week, 4 hours each) and receive three different dialyzer membranes in a crossover design, one for each session with a total study duration of 1 week. During each session blood samples will be collected (at baseline, hourly, and at the end of dialysis) and additionally, after each session, the used dialysis circuit will be rinsed to recover adherent cells. The study aims to: * Assess whether the dialyzer membrane influences leukocyte and platelet activation . * Evaluate whether the dialyzer membrane influences neutrophil extracellular trap (NET) formation. * Evaluate whether the dialyzer membrane influences the transcriptomic profiles of immune cells.
Trial Details
NCT Number NCT07682701
Lead Sponsor Universitair Ziekenhuis Brussel
Collaborators: Vrije Universiteit Brussel, NIER research group, University of Rochester
Conditions Hemodialysis, End Stage Renal Disease (ESRD), Hemodialysis Treatment, Thromboinflammation
Enrollment 10 participants
Start Date 2026-04-13
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-06